Cardiac POC Testing Devices

Cardiac POC Testing Devices

Global Cardiac POC Testing Devices Market to Reach US$2.2 Billion by 2030

The global market for Cardiac POC Testing Devices estimated at US$1.5 Billion in the year 2023, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2023-2030. Cardiac Markers Test, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Analyzers segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$558.3 Million While China is Forecast to Grow at 6.7% CAGR

The Cardiac POC Testing Devices market in the U.S. is estimated at US$558.3 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$258.4 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Cardiac POC Testing Devices Market - Key Trends and Drivers Summarized

Cardiac Point-of-Care (POC) testing devices are medical tools designed to provide immediate and accurate diagnostic results at or near the site of patient care. These devices are crucial in the rapid diagnosis and management of cardiovascular conditions, including heart attacks, heart failure, and other cardiac-related emergencies. Cardiac POC testing devices typically include handheld devices, portable analyzers, and compact lab-in-a-box systems that measure biomarkers such as troponin, BNP (B-type natriuretic peptide), and D-dimer from a small blood sample. The primary advantage of these devices lies in their ability to deliver quick results, often within minutes, thereby facilitating prompt clinical decision-making and improving patient outcomes.

The deployment of cardiac POC testing devices has revolutionized the approach to diagnosing and managing cardiac conditions. Traditionally, diagnosing heart-related issues required sending samples to centralized laboratories, resulting in longer turnaround times. Cardiac POC testing devices mitigate this delay by providing on-the-spot results, which is critical in emergency settings where time is of the essence. Hospitals, emergency departments, ambulances, and even remote clinics have increasingly adopted these devices to enhance their diagnostic capabilities. Furthermore, advancements in sensor technology and microfluidics have significantly improved the accuracy and reliability of cardiac POC testing, making them a valuable tool for healthcare professionals.

The growth in the cardiac POC testing devices market is driven by several factors. The increasing prevalence of cardiovascular diseases, coupled with the growing demand for rapid and accurate diagnostic tools, is a primary driver of market expansion. Technological advancements, including the miniaturization of devices and the integration of digital health solutions, have made these devices more accessible and user-friendly, boosting their adoption across various healthcare settings. The shift towards decentralized healthcare, emphasizing point-of-care diagnostics to reduce the burden on centralized labs and hospitals, also contributes to market growth. Additionally, the rising awareness about the importance of early diagnosis and the management of cardiac conditions among patients and healthcare providers further propels the demand for these devices. Regulatory support and favorable reimbursement policies in many regions enhance market penetration and accessibility.

Select Competitors (Total 50 Featured) -

• Abbott Laboratories, Inc.
• Danaher Corporation
• HemoCue AB
• Alfa Scientific Designs, Inc.
• BG Medicine, Inc.
• Boditech Med, Inc.
• Jant Pharmacal Corporation
• Creative Diagnostics
• AccuBioTech Co., Ltd.
• BIOBASE
• DiaSys Diagnostics India Pvt., Ltd.
• Biosynex SA
• Humasis Co Ltd
• Diagnoptics
• CTK Biotech, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.